Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: http://www.eurosurveillance.org / ViewArticle.aspx?ArticleId=21169


In this issue


Home Eurosurveillance Edition  2011: Volume 16/ Issue 50 Article 3
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 16, Issue 50, 15 December 2011
Rapid communications
A case of diphtheria in Sweden, October 2011
  1. Örebro University Hospital, Department of Laboratory Medicine, Clinical Microbiology, Örebro, Sweden
  2. Swedish Institute for Communicable Disease Control (SMI), Solna, Sweden

Citation style for this article: Fredlund H, Norén T, Lepp T, Morfeldt E, Henriques Normark B. A case of diphtheria in Sweden, October 2011. Euro Surveill. 2011;16(50):pii=20038. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20038
Date of submission: 25 November 2011

In October 2011, a child who had arrived in Sweden from Somalia presented with atypical tonsillitis, was treated with penicillin and the symptoms resolved. A throat swab was positive for toxigenic Corynebacterium diphtheriae. The child’s family were then vaccinated with diphtheria, tetanus and pertussis vaccine and screened for C. diphtheriae. No secondary cases were found. A high level of adherence to childhood vaccination programmes is an effective way to protect populations against diphtheria.


Case report

In October 2011, a child who had recently migrated with their family from Somalia presented at a local general practitioner’s (GP’s) practice in Sweden with a sore throat and fever (40 °C). An atypical picture of unilateral tonsillitis led to the child being admitted to hospital, where penicillin was administered intravenously. The child was discharged the following day and was then treated at home with oral penicillin for one week, after which time the symptoms resolved. The other family members were healthy.

A throat swab taken on admission to hospital was cultured. The culture was positive for group A beta-haemolytic streptococci. Due to the referral information of tonsillitis in a person who had recently arrived in the country and given the atypical clinical presentation, the local laboratory also cultured for Corynebacterium diphtheriae, which was positive. The isolate was fully sensitive to penicillin and erythromycin. Further analysis using PCR to detect the diphtheria toxin gene and the Elek test at the Swedish Institute for Communicable Disease Control (SMI, Solna) verified that the isolate was a toxin-producing strain of C. diphtheriae.

Control measures

Once the laboratory results had been obtained, the child’s family (parent and seven children), were immediately vaccinated with diphtheria, tetanus and pertussis (DTP) vaccine and screened for C. diphtheriae. Only one sibling was found to carry C. diphtheriae and was treated with oral penicillin. This C. diphtheriae strain was later shown to be non-toxigenic.

The family had arrived in Sweden four weeks before the case’s illness from a refugee camp in Africa. They had lived at one address since their arrival and had no other relatives in Sweden. There was no history of the case having attended daycare or school during the incubation period. As the family had had limited contact with others, contact tracing was not needed. The hospital staff had very limited contact (one overnight stay) with the patient who received immediate antibiotic treatment. Checking of vaccination history confirmed that all staff were fully vaccinated against diphtheria. All were healthy when the disease was diagnosed several days later, and to date still are. Follow-up of the family has been carried out by the local nurse, responsible for migrant health, and GP and to date, no secondary case has been detected.

Background

Diphtheria is caused by toxin-producing C. diphtheriae, C. ulcerans, and C. pseudotuberculosis. The best known and most widely studied species is C. diphtheriae, the most common causal agent of the disease.

The disease can result in an acute upper respiratory tract infection characterised by sore throat, fever (often <38 °C) and an adherent membrane on the tonsils, pharynx and/or nasal cavity. The severity of diphtheria is related to the degree of obstruction of the upper respiratory tract, caused by an acute bacterial toxic infection, and dissemination of the toxin which can cause myocarditis, polyneuritis and other systemic toxic effects. Overall, the case fatality rate may be as high as 20–30% in toxic forms [1]. A milder form of diphtheria may be restricted to cutaneous lesions even when caused by toxin-producing strains. The causative bacteria are spread by direct physical contact or breathing aerosolised secretions.

Due to the high degree of susceptibility of children to diphtheria, vaccination at an early age is universally advocated, for example, with DTP vaccine. Once quite common, diphtheria is rarely seen in developed nations due to the widespread use of DTP vaccine. Two minor outbreaks of diphtheria were notified in Sweden during the 1980s [2,3] and only two cases of the disease due to C. diphtheriae have been diagnosed since 2001 (data not shown). Both cases were imported. The relative absence of diphtheria in Sweden is primarily due to the high vaccination coverage obtained through the childhood immunisation programme initiated in the 1950s. According to the programme, all children born in Sweden should receive four doses of diphtheria toxoid-containing vaccine. The first three doses should be administered within three months of age and the fourth dose should be given at the age of 10 years. All children of migrants are offered DTP immunisation as soon as they are in the Swedish health care system, often within weeks but at the latest within a few months after their arrival in Sweden. In 2010, a nationwide vaccination survey showed that 96% of all children aged 13 years living in Sweden were fully vaccinated with DTP vaccine and 2% were partly vaccinated (data not shown).

Discussion

Bacteriological analysis of a throat swab of the case reported here showed the presence of beta-haemolytic streptococci and toxigenic C. diphtheriae. Both pathogens may well have contributed to the clinical picture and the patient was successfully treated with penicillin. 

In a country where the occurrence of diphtheria is low, such as Sweden, specific culturing for C. diphtheriae, C. ulcerans and C. pseudotuberculosis is rarely performed. Usually throat swabs are cultured without searching for these pathogens. As special media are required, a specific request for this culture has to be included on the referral note to the diagnostic laboratory, along with an indication of the unusual features of the disease and/or the origin of the patient. The local laboratory has to take that information into account for appropriate culturing. Otherwise diphtheria could be overlooked at an early stage of the disease or when presenting with atypical features and may cause secondary cases among susceptible people.

Diphtheria is a rarely diagnosed disease in western Europe and the small number are most commonly associated with travel to endemic countries. A few case reports from the United Kingdom and France have been published in recent years [4-6].

A high level of adherence to childhood vaccination programmes in every country is an effective way to protect populations against diphtheria. Adequate diagnostic tools and appropriate treatment of cases with atypical tonsillitis are also paramount to prevent further cases and potential outbreaks.



References
  1. Eskola J, Lumio J, Vuopio-Varkila J. Resurgent diphtheria – are we safe? Br Med Bull. 1998;54(3):635-45.
  2. Björkholm B, Olling S, Larsson P, Hagberg L. An outbreak of diphtheria among Swedish alcoholics. Infection. 1987;15(5):354-8.
  3. Christenson B, Hellström L, Aust-Kettis A. Diphtheria in Stockholm, with a theory concerning transmission. J Infect. 1989;19(2):177-83.
  4. Perkins S, Cordery R, Nixon G, Abrahams A, Andrews J, White J, et al. Investigations and control measures following a non-travel-associated case of toxigenic Cornyebacterium diphtheriae, London, United Kingdom, December 2009-January 2010. Euro Surveill. 2010;15(16):pii=19544. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19544
  5. Taylor J, Saavedra-Campos M, Harwood D, Pritchard G, Raphaely N, Kapadia S, et al. Toxigenic Corynebacterium ulcerans infection in a veterinary student in London, United Kingdom, May 2010. Euro Surveill. 2010;15(31):pii=19634. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19634 
  6. Rousseau C, Belchior E, Broche B, Badell E, Guiso N, Laharie I, et al. Diphtheria in the south of France, March 2011 . Euro Surveill. 2011;16(19):pii=19867. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19867 


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.